• NovaBridge Biosciences appointed Mark Hagler as president and chief commercial officer.
• Hagler previously built commercial strategy for Abraxane in new indications.
• He also led global launch of a core Afinitor indication.
• Role adds commercial leadership as NovaBridge advances givastomig toward registrational pivotal studies in first-line gastric cancer.
• Appointment also supports pre-commercial readiness for VIS-101, a dual VEGF-A x ANG-2 inhibitor program in wet AMD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220700PRIMZONEFULLFEED9694717) on April 22, 2026, and is solely responsible for the information contained therein.